



Healthcare  
Improvement  
Scotland

SMC  
Advice on new  
medicines

[www.scottishmedicines.org.uk](http://www.scottishmedicines.org.uk)

Statement of advice  
SMC2483

# belimumab 120mg, 400mg powder for concentrate for solution for infusion and 200mg solution for injection in pre-filled pen (Benlysta®)

GlaxoSmithKline UK

4 March 2022

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation **belimumab (Benlysta®)** is not recommended for use within NHSScotland.

**Indication under review:** In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**  
**Scottish Medicines Consortium**

Published 11 April 2022